Carranza-Naval MJ, Del Marco A, Hierro-Bujalance C, et al
Since 2005, multiple GLP-1R agonists resembling exendin-4 have been developed ( Figure 2 ), with fatty-acid modifications to increase half-life and facilitate less frequent dosing regimes
While this amplifies the effect, it doesnt necessarily increase the long-term risk if the protocol includes proper cycling and monitoring
How the 1999 Ghrelin Discovery Reframed the Target A conceptual shift arrived in December 1999, when Kojima and colleagues at Kurume University identified ghrelin, a 28-amino-acid acylated peptide predominantly produced by gastric X/A-like cells, as the endogenous ligand for GHS-R1a
As mitochondria play a role in a variety of diseases, like Alzheimer's disease (AD), Parkinson's disease (PD), diabetes, acute myocardial infarction, and stroke, therapeutic intervention includes replenishment of the mitochondrial pool through artificial transfer [33, 34]
So rather than asking NAC or Glutathione, the smarter question is: Whats your goal, fast defense or foundational repair
